Literature DB >> 12006540

DNA sequence losses on chromosomes 11p and 18q are associated with clinical outcome in lymph node-negative ductal breast cancer.

Athanassios Dellas1, Joachim Torhorst, Elisabeth Schultheiss, Michael J Mihatsch, Holger Moch.   

Abstract

PURPOSE: Histological and other markers alone cannot predict the risk of disease progression in node-negative breast cancer. Several genomic aberrations have been linked to clinical outcome in breast cancer. EXPERIMENTAL
DESIGN: In this study, comparative genomic hybridization was applied to screen for specific DNA copy number gains and losses in 20 pT1/pT2 node-negative invasive ductal carcinomas with no disease recurrence with at least 8 years of follow-up and in 20 pT1/pT2 node-negative tumors with distant disease recurrence.
RESULTS: The number of genomic aberrations (copy number gains and losses) per tumor was significantly higher in tumors with disease recurrence (P < 0.05). The number of genomic aberrations was associated with histological grade (P < 0.02). Within the group of tumors with disease recurrence, the total number of genetic aberrations per tumor (P < 0.02) and the number of DNA sequence losses per tumor (P < 0.01) were significantly associated with poor survival. Of the individual loci involved, only losses at chromosomes 11p (P < 0.002) and 18q (P < 0.004) were associated with poor survival in the recurrence group. Histological grade and loss of 18q were independent prognostic variables in multivariate analysis.
CONCLUSIONS: This genome-wide analysis by comparative genomic hybridization suggests that node-negative ductal breast cancers with a high number of genomic aberrations have an increased risk of disease recurrence. The number of DNA sequence losses, particularly losses of chromosomes 11p and 18q, were associated with poor prognosis. Genes on chromosomes 11p and 18q may play a role in the progression of ductal breast carcinoma.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12006540

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  13 in total

Review 1.  The role of estrogen in the initiation of breast cancer.

Authors:  J Russo; Irma H Russo
Journal:  J Steroid Biochem Mol Biol       Date:  2006-12       Impact factor: 4.292

2.  Molecular alterations associated with breast cancer mortality.

Authors:  Laura M Voeghtly; Kim Mamula; J Leigh Campbell; Craig D Shriver; Rachel E Ellsworth
Journal:  PLoS One       Date:  2012-10-04       Impact factor: 3.240

3.  Genomic alterations identified by array comparative genomic hybridization as prognostic markers in tamoxifen-treated estrogen receptor-positive breast cancer.

Authors:  Wonshik Han; Mi-Ryung Han; Jason Jongho Kang; Ji-Yeon Bae; Ji Hyun Lee; Young Ju Bae; Jeong Eon Lee; Hyuk-Jae Shin; Ki-Tae Hwang; Sung-Eun Hwang; Sung-Won Kim; Dong-Young Noh
Journal:  BMC Cancer       Date:  2006-04-12       Impact factor: 4.430

4.  Mapping of Mcs30, a new mammary carcinoma susceptibility quantitative trait locus (QTL30) on rat chromosome 12: identification of fry as a candidate Mcs gene.

Authors:  Xuefeng Ren; Jessica C Graham; Lichen Jing; Andrei M Mikheev; Yuan Gao; Jenny Pan Lew; Hong Xie; Andrea S Kim; Xiuling Shang; Cynthia Friedman; Graham Vail; Ming Zhu Fang; Yana Bromberg; Helmut Zarbl
Journal:  PLoS One       Date:  2013-09-02       Impact factor: 3.240

5.  Differences and homologies of chromosomal alterations within and between breast cancer cell lines: a clustering analysis.

Authors:  Milena Rondón-Lagos; Ludovica Verdun Di Cantogno; Caterina Marchiò; Nelson Rangel; Cesar Payan-Gomez; Patrizia Gugliotta; Cristina Botta; Gianni Bussolati; Sandra R Ramírez-Clavijo; Barbara Pasini; Anna Sapino
Journal:  Mol Cytogenet       Date:  2014-01-23       Impact factor: 2.009

6.  Analysis of PALB2/FANCN-associated breast cancer families.

Authors:  Marc Tischkowitz; Bing Xia; Nelly Sabbaghian; Jorge S Reis-Filho; Nancy Hamel; Guilan Li; Erik H van Beers; Lili Li; Tayma Khalil; Louise A Quenneville; Atilla Omeroglu; Aletta Poll; Pierre Lepage; Nora Wong; Petra M Nederlof; Alan Ashworth; Patricia N Tonin; Steven A Narod; David M Livingston; William D Foulkes
Journal:  Proc Natl Acad Sci U S A       Date:  2007-04-09       Impact factor: 11.205

Review 7.  Taxane benefit in breast cancer--a role for grade and chromosomal stability.

Authors:  Roger P A'Hern; Mariam Jamal-Hanjani; A Marcell Szász; Stephen R D Johnston; Jorge S Reis-Filho; Rebecca Roylance; Charles Swanton
Journal:  Nat Rev Clin Oncol       Date:  2013-05-07       Impact factor: 66.675

8.  Clinical relevance of loss of 11p15 in primary and metastatic breast cancer: association with loss of PRKCDBP expression in brain metastases.

Authors:  Harriet Wikman; Bettina Sielaff-Frimpong; Jolanthe Kropidlowski; Isabell Witzel; Karin Milde-Langosch; Guido Sauter; Manfred Westphal; Katrin Lamszus; Klaus Pantel
Journal:  PLoS One       Date:  2012-10-31       Impact factor: 3.240

9.  An array CGH based genomic instability index (G2I) is predictive of clinical outcome in breast cancer and reveals a subset of tumors without lymph node involvement but with poor prognosis.

Authors:  Françoise Bonnet; Mickael Guedj; Natalie Jones; Sana Sfar; Véronique Brouste; Nabila Elarouci; Guillaume Banneau; Béatrice Orsetti; Charlotte Primois; Christine Tunon de Lara; Marc Debled; Isabelle de Mascarel; Charles Theillet; Nicolas Sévenet; Aurélien de Reynies; Gaëtan MacGrogan; Michel Longy
Journal:  BMC Med Genomics       Date:  2012-11-27       Impact factor: 3.063

10.  Amplification of HER2 is a marker for global genomic instability.

Authors:  Rachel E Ellsworth; Darrell L Ellsworth; Heather L Patney; Brenda Deyarmin; Brad Love; Jeffrey A Hooke; Craig D Shriver
Journal:  BMC Cancer       Date:  2008-10-14       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.